 Myasthenia gravis is a chronic autoimmune neuromuscular disease that is characterized by different degrees of weakness of the skeletal muscles of the.

Slides:



Advertisements
Similar presentations
MUSCULAR SYSTEM.
Advertisements

Neurological Diseases Jerry Carley RN, MSN, MA, CNE
FACULTY OF MEDICINE PHYSIOLOGY DEPARTMENT DR. NERMEN MADY DR. RAMEZ.
Myasthenia Gravis Dr. Belal M. Hijji, RN. PhD February 29, 2012.
Muscle weakness Index case Year 1 Michaelmas Term.
Guillain-Barré Syndrome, Myasthenia Gravis,
Terri Kueber, CRNA, MS. Explain the pathophysiology and classification of Myasthenia Gravis (MG) List the signs and symptoms and clinical manifestation.
Synaptic transmission *** Synapse is the junction between two neurones where electrical activity of one neurone is transmitted to the other.
NEUROMUSCULAR JUNCTION DR. ZAHOOR ALI SHAIKH LECTURE
Nuha Alkhawajah MD.   Disorders affecting the junction between the presynaptic nerve terminal and the postsynaptic muscle membrane  Pure motor syndromes.
Therapeutic Plasma Exchange for Myasthenia Gravis Clifford Blieden, MD Houston Methodist Hospital Department of Pathology and Genomic Medicine, Division.
1 Review of Musculoskeletal System Chapter Muscle Skeletal muscle > 600 muscles in body Fascia –Epimysium – forms tendons at ends –Perimysium –
NEUROMUSCULAR JUNCTION BLOCKERS BY :DR ISRAA OMAR.
Myasthenia Gravis Blaine Suing November 21 st 2007.
Thyroid and Thymus Gland
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
The Muscular System By: Amy Saliba, Vanessa Perez, Diego Saenz, Javier Gonzalez.
GENERAL THORACIC SURGERY CHAPTER 168
Graves Disease Taylor Dobbs.
Myasthenia Gravis 重症肌无力(MG)
Myasthenia Gravis.  Describe myasthenia gravis  Signs and Symptoms of the disease  Describe the treatments available Purpose and Objectives.
The Nervous System The Spinal Cord & Spinal Nerves
MYASTHENIA GRAVIS (MG)
Sophia M. Chung, M.D. Depts of Ophthalmology &
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Myasthenia Gravis Victor Politi,M.D.
MYASTHENIA GRAVIS ANESTHESIOLOGY Jasdeep Dhaliwal Clinical Rotation.
The Sliding Filament Theory Slide 6.18 Copyright © 2003 Pearson Education, Inc. publishing as Benjamin Cummings Figure 6.8.
Linda S. Williams / Paula D. Hopper Copyright © F.A. Davis Company Understanding Medical Surgical Nursing, 4th Edition Chapter 50 Nursing Care of.
Medical and Surgical Management of MG Brian A. Crum, MD Department of Neurology Mayo Clinic Rochester, MN MGFA National Meeting, St. Louis May, 2010.
The Nervous and Immune Systems
Musculoskeletal Injuries. Definition Any injury that occurs to a skeletal muscle, tendon, ligament, joint, or a blood vessel that services skeletal muscle.
B) Reactions to Transplantation  Transplants may be attacked by T cells, macrophages, and complement-fixing antibodies.  Transplants to privileged sites.
NEUROMUSCULAR JUNCTION BLOCKERS
Chapter 9 Muscular System
Disorders of the Neuromuscular Junction
Prolonged, painful involuntary contraction of skeletal muscle. Caused by: An imbalance of the salts in the body, fatigue, or stress Symptoms: Pain.
Amyotrophic Lateral Sclerosis (ALS)
ANTICHOLINESTERASES Acetylcholinesterase is an enzyme that specifically cleaves acetylcholine to acetate and choline. It is located both pre-and post-synaptically.
Myasthenia Gravis.
Neurology Chapter of IAP
Myasthenia Gravis: An inheritable disorder or an acquired auto-immune response Research in Allied Health Jeri Frazier November 1, 2005.
NEUROPATHY Subsection B3 Francisco – Go, Kerby + Laxamana September 16, 2009.
MYASTHENIA GRAVIS Aswad H. Al.Obeidy FICMS, FICMS GE&Hep Kirkuk General Hospital.
MYASTHENIA GRAVIS “FROM WEAKNESS SHALL COME STRENGTH”. BY PATTI HAMILTON.
Myasthenia Gravis Anastasiya Lukecha Psychology 4th.
Emmett West Hour Myasthenia Gravis Muscular System.
Kaitlyn Bradshaw. Is a rapid pain under any voluntary muscle DESCRIPTION.
Diseases and Disorders
Autonomic Nervous System (ANS) Cholinergic Drugs 4 أ0م0د.وحدة بشير اليوزبكي.
Nursing management of Myasthenia Gravis
Outcome of Thymectomy in Juvenile Myasthenia Gravis
Myasthenia Gravis.
Myasthenia Gravis.
Jennifer Vilarino Period: 5
Neuromuscular disorders
Neuromuscular junction
Muscular Disorders and Diseases
a presentation on auto-immune disorders
Pathology of the Muscular System.
Myasthenia Gravis Johan Perrand Period 3.
Myasthenia gravis By: Nikki Young.
“Grave Muscle Weakness”
Skeletal Muscle Pathology For Second Year Dental Students
Chapter 6 Muscarinic [,mʌskə‘rinik]毒蕈碱的 receptor agonists
Myasthenia Gravis By: Cheryl Hamilton.
Presentation transcript:

 Myasthenia gravis is a chronic autoimmune neuromuscular disease that is characterized by different degrees of weakness of the skeletal muscles of the body. The name myasthenia gravis came from a Latin and Greek origin meaning grave muscle weakness.

 Myasthenia Gravis is termed an autoimmune disease. The immune system usually makes antibodies to attack bacteria, viruses and germs. With the autoimmune disease, the immune system makes antibodies against parts of ones own body tissues.

 Although there is no direct cause known for why the body starts to produce the antibodies that destroy the acetylcholine receptors, it is believed to be related to the thymus gland since it also produces antibodies.

Onset usually occurs in women in the year rage and men in the year range Myasthenia gravis affects approximately 20 in 100,000 people

 In a person with normal immune system, muscles are stimulated to contract by the transmission of nerve impulses to the muscle fibers. The nerve impulses cause neurotransmitter acetylcholine to be released into the synaptic cleft. There it is picked up by the acetylcholine receptors on the muscle fiber.

 In myasthenia gravis, the numbers of acetylcholine receptors appear to be reduced. There is evidence to indicate that the receptor deficit is caused by an attack on the acetylcholine receptors by the body's own immune system.

 With the numbers of acetylcholine receptors reduced, it causes the nerve impulse to be prevented from reaching the muscles. The result is weakness and rapid fatigue only in the affected muscles.

 About 60 % patients have weakness in the eye muscles, termed ocular myasthenia. The majority of other patients will go on to develop weakness in other muscle groups.

 Other types of myasthenia gravis include congenital MG, which is an inherited condition caused by a genetic defect instead of an immune disorder  It develops in an infant shortly after being born to a mother with myasthenia gravis and usually has generalized symptoms.

 Transient neonatal MG is a temporary condition that develops in approximately % of infants born to a mother with myasthenia gravis

 It is caused by the circulation of the mothers antibodies through the placenta and lasts as long as the mothers antibodies remain in the infant.

 Ocular manifestations  – Ptosis, uni- or bilateral is very common and may occur while patients reading, or during long period of driving

 Difficulty chewing, speaking, or swallowing: initial symptoms in 17% of patients  Fatigability and weakness during mastication  Unable to keep jaw closed after chewing  Slurred and nasal speech

 Up to 75% of Pt’s have abnormality of thymus  25% have thymoma, tumor (either benign or malignant) of thymus

 Limb muscles weakness:  – Initial symptoms in fewer than 10%  – Upper extremities weakness is more common than lower extremities, asymmetrical  – Involve proximal muscles than distal  – Involve neck muscles: neck flexion weaker than neck extension

 Possible association  – Anticholinergic drugs (artane);  – Anti-infectives (ampicillin, imipenem, erythromycin)  – Cardiovascular drugs (propafenone HCl, verapamil);  – Cholroquine phosphate  – Neuromuscular-blocking drugs (vecuronium,  succinylcholine)

 Osserman Classification  Grade I: involve focal disease (restricted to  ocular muscle)  Grade II: generalized disease  IIa: mild  IIb: moderate  Grade III: severe generalized disease  Grade IV: a crisis with life-threatening impairment of respiration

 The goal is to achieve remission By increased neuromuscular transmission  Reduce autoimmunity

blood tests are done to detect the abnormal antibody that destroys the receptors  If spread out, in 2 y – thymectomy  Acetylcholine-receptor antibody levels fall  Immunosuppressive therapy  Cyclosporine  Inhibits T-cell activation

 Electromyography Repetitive Nerve Stimulation to check for a post-synaptic defect or a muscle biopsy to look for antibodies may also be used. Serologic tests(test clear portion of the blood) may be used Chest x-ray

 MG is usually not fatal but in the case of a myasthenia crises occurrence (when muscles needed for breathing are affected), hospitalization and intensive care may be necessary to aid breathing with a respirator.

Management  – Stop every medications  – Assisted ventilation

 Vecuronium  Succinylcholine  Fentanyl

  g.cfm g.cfm  avis avis  theniagravis.html theniagravis.html  brainBriefings_MyastheniaGravis brainBriefings_MyastheniaGravis